Skip to main content
Publications
Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Hampe M, Cai C, Chassot-Agostinho C, Reynolds M , Sherif B , Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the GEOMETRY mono-1 study . Eur J Cancer. 2023 Apr;183:98-108. doi: 10.1016/j.ejca.2022.10.030
Lin S, Kahangire DA, Nagar S , Ahn M, Affi R, Agulnik J, Shih J, Hockmair MJ, Tufman A, Debieuvre D, Chow J, Jimenez M , Davis KL , Sandelin M, Veluswamy R. Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study . Poster presented at the European Lung Cancer Congress 2023; March 31, 2023. Copenhagen, Demark.
Simmons DJ, Blank SV, Nagar S , Nham T , Long GH, Davis KL , Wetherill G, Munley J, McLaurin K. Real-world evaluation of PARP inhibitor tolerability in advanced ovarian cancer: retrospective US cohort study . Poster presented at the SGO 2023 Annual Meeting on Women's Cancer; March 27, 2023. Tampa, FL.
Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D , Sherif B , Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day . Cancer Med. 2023 Feb;12(4):4332-42. doi: 10.1002/cam4.5308
Grivas P, Barata PC, Moon H, Hutson TE, Gupta S, Sternberg CN, Dave V, Downey C , Shillington AC, Devgan G, Kirker M, Thakkar S, Katzenstein HM, Bhanegaonkar A, Liu F, Brown J, Sonpavde GP. Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II) . Poster presented at the 2023 ASCO Genitourinary Cancers Symposium; February 16, 2023. San Francisco, CA. [abstract] J Clin Oncol. 2023 Feb 1; 41(Suppl 4). doi: 10.1200/JCO.2023.41.6_suppl.465
Bergerot C, Young Rha S, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Lyun Lee J, Sunela K, Ciuleanu T, Heng D, Glen H, Wang J , Bennett L , Pan J, O'Hara K, Puente J. Health-related quality of life outcomes with two different starting doses of lenvatinib in combination with everolimus for previously treated renal cell carcinoma . Oncologist. 2023 Jan 18;28(1):59-71. doi: 10.1093/oncolo/oyac142
Ahn M, Kang JH, Kim S, Kahangarie D, Nagar SP , Davis KL , Jimenez M , Seo M, Jung M, Sandelin M, Cho BC. Treatment (tx) patterns and outcomes in resectable early-stage NSCLC in South Korea: subgroup analysis of a global real-world (rw) study . Poster presented at the ESMO Asian Congress 2023; December 2, 2023. Singapore, China. [abstract] Ann Oncol. 2023; 34(Suppl 4):S1646-53.
Furqan M, Karanth S , Goyal RK , Shih Y, Cai B, Rombi J , Davis KL , Caro N, Saliba TR. Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14) . Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL. [abstract] J Clin Oncol. 2023; 4((Suppl 16):e21112.
Shih JY, Lin SH, Nagar SP , Davis KL , Jimenez MI , Kahangire DA, Servidio L, Ho L, Veluswamy R. Treatment patterns in resectable early-stage NSCLC in Taiwan: subgroup analysis of a global real-world study . Poster presented at the 2022 ESMO Asia Congress; December 2, 2022. Singapore, Republic of Singapor.
Fernandez M, Bell TJ, Khan S , Tumminello B, Bektas M , Heyes CE , Oton AB. Burden of illness of desmoid tumors . Poster presented at the 2022 CTOS Annual Meeting; November 16, 2022. Vancouver, Canada. Previously presented at the 2022 Desmond Tumor Research Foundation (DTRF) Annual Meeting.
Bonastre J, Negrier S, Colrat F, Chamielec C, Teitsson S, Knight C, Ni L , Chevalier J, Gaudin AF, Roupret M, Branchoux S. Impact of method for modelling distant recurrence (DR) on cost-effectiveness (CE) of nivolumab (NIVO) as an adjuvant treatment of muscle-invasive urothelial carcinoma (MIUC) patients with high risk of recurrence in France . Presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria.
Veluswamy R, Ahn MJ, Nagar S , Affi R, Agulnik J, Shih JY, Hochmair MJ, Tufman A, Debieuvre D, Jimenez MI , Davis K , Kahangire DA, Servidio L, di Perna C, Lin SH. Surgical resection, treatment patterns and outcomes in patients (pts) with early-stage non-small cell lung cancer (NSCLC): interim analysis of a global real-world study . Poster presented at the 2022 International Thoracic Surgical Oncology Summit; September 30, 2022. New York, NY.
Spira A, Zhou X , Liao L, Yu E, Chen L, Lau A, Wang Y, Gnanasakthy A , Radford J, Hamadani M. Health-related quality of life and tolerability in patients with/without skin toxicity during loncastuximab tesirine treatment in a phase 2 clinical trial (LOTIS-2) . Poster presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022); September 28, 2022. Houston, TX.
Wainberg ZA, Enzinger PC, Qin S, Yamaguchi K, Gnanasakthy A , Taylor K, Jamotte A, Majer I, Kang YK. Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6 . Poster presented at the 2022 ESMO Annual Conference; September 9, 2022. Paris, France.
Stattin P, Westerberg M, Franck Lissbrant I, Hjalm-Eriksson M, Kjellman A, Ullen A, Vassilev Z, Sandstrom P, Weinrib R , Martinez D , Garcia de Albeniz Martinez X . Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden . Clin Genitourin Cancer. 2022 Sep 9;S1558-7673(22):00194-X. doi: 10.1016/j.clgc.2022.09.002
Salles G, Schuster SJ, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith S, Davis KL , Ubieto A, Nagar S , Zhang AJ, Bollu V, Jousseaume E, Ramos R, Wang Y, Link BK. A retrospective cohort study of treatment outcomes of adult patients with relapsed or Refractory Follicular Lymphoma (ReCORD-FL) . Hemasphere. 2022 Jun 21;6(7):e745. doi: 10.1097/HS9.0000000000000745
Diez-Campelo M, Yucel A, Goyal R , Parikh R , Dhuliawala S, Jimenez M , Sluga-O'Callaghan M , Hughes C, Tang D, Germing U. Systemic therapy utilization and hematologic outcomes in lower-risk myelodysplastic syndromes (LR-MDS): findings from a real-world medical record review study in the US, UK, and Europe (EU) . Poster presented at the 2022 European Hematology Association Hybrid Congress; June 10, 2022. Vienna, Austria.
Spira A, Liao L, Zhou X , Gnanasakthy A , Chen L, Ungar D, Yu E, Kilavuz T, Radford J, Hamadani M. Health-related quality of life and tolerability of loncastuximab tesirine in high-risk patients with relapsed/refractory diffuse large B-cell lymphoma treated in a phase 2 clinical trial (LOTIS 2) . Poster presented at the 2022 EHA Congress; June 9, 2022. Vienna, Austria.
Lin SH, Ahn M, Nagar S , Affi R, Agulnik J, Shih J, Hochmair MJ, Tufman A, Debieuvre D, Jimenez MI , Davis K , Kahangire DA, Servidio L, Veluswamy R. Treatment patterns and outcomes in resectable early stage NSCLC: interim analysis of a global real-world study . Poster presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2022. Chicago, IL.
Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L , Wang J , Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study . Lancet Oncol. 2022 Jun;23(6):768-80. doi: 10.1016/S1470-2045(22)00212-1
Kummar S, Shen L, Martinus van Tilburg C, Tan DSW, Doz F, McDermott RS, Zwaan CM, Keating KN, Chirila C , Norenberg R, Fellous MM, Brega N, Xu R, Laetsch TW, Drilon AE, Hong DS. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials . Poster presented at the 2022 ASCO Annual Meeting; June 3, 2022. Chicago, IL. [abstract] Am J Clin Oncol. 2022 Jun; 40(16_suppl):6563. doi: 10.1200/JCO.2022.40.16_suppl.6563